← SynDRA
LAPATINIB
SynDRA canonical compound SYN0000785 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | ERBB2 |
|---|
| Mechanism of action | ErbB2 inhibitor |
|---|
| Indication | breast cancer |
|---|
| Disease area | oncology |
|---|
All known targets
- EGFR
- ERBB2
- ABCB1
- MAP2K7
- STK10
- SLK
- SLCO1B1
- RIPK2
- PIK3C2G
- PIK3C2B
- PI4KB
- PDGFRB
Mechanisms of action (all sources)
- EGFR INHIBITOR
- ERBB2 INHIBITOR
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- Epidermal growth factor receptor erbB1 inhibitor
- EEF2K INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- KCNH2
- AURKB
- CYP3A4
- SYK
- RET
- SRC
- YES1
- ABCB11
- PHKG2
- PHKG1
- PGRMC1
- PFKP
- PASK
- PEBP1
- PDXK
- PDPK1
- PDGFRA
- PCYT1A
- PBK
- AAK1
- PAK6
- PAK5
- PIK3CA
- PAK3
- PAK2
- PAK1
- PAICS
- OXSR1
- OPA1
- OLA1
- NUAK2
- NUAK1
- NTRK3
- NTRK2
- PAK4
- PIK3CG
- PIK3CB
- PLK1
- PRKCA
- PRKAR2A
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ACM1
- ANDR
- PRGR
- NSD2
- NF2L2
- KSYK
- IFNG
- IFNB1
- HSPB1
- GLI3
- ESRRA
- ESR1
- CP3A7
- CP3A4
- CP2D6
- CP2CJ
- CP2C9
- CASP7
- CASP3
- TP53
Drug classes
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Kinase Inhibitor
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- LAPATINIB DITOSYLATE
- TYKERB
- Tykerb
- lapatinib tosilate hydrate
- lapatinib tosilate
- GW 572016X
- tyverb
- lapatinib ditosylate
- GW572016F
- lapatinib ditosilate
- lapatinib ditosilate hydrate
- lapatinib ditosylate hydrate
- FMM
- GSK-572016
- GSK572016
- GW-2016
- GW-572016
- GW-572016X
- GW2016
- GW572016
- LAPATANIB
- LAPATINIB (FREE BASE)
- LAPATINIB (GW-572016)
- Lapatinib ditosylate
- Lapatinib ditosylate monohydrate
- Tyverb
- Tycerb
- Lapatinib Ditosylate
- Lapatinib [INN]
- Lapatinib tosilate hydrate
- GSK 572016
- GW 572016
- Lapatinib (INN)
- Tykerb (TN)
- Lapatinib, Tykerb, GW572016
- Lapatinib (ERBB2 inhibitor)
- Lapatinib base
- Lapatinib free base
Reported adverse events
- Hepatotoxicity
- Epistaxis
- Fatigue
- Headache
- Hypersensitivity
- Insomnia
- Nail disorder
- Pain
- Pain in extremity
- Rash
- Ventricular arrhythmia
- Alopecia
Look up LAPATINIB in the interactive SynDRA portal →